Transcriptional adaptation after deletion of Cdc42 in primary T cells.
Published version
Peer-reviewed
Repository URI
Repository DOI
Type
Change log
Authors
Abstract
Cdc42 is a Rho family GTPase known for its central role in cell polarity and cytoskeletal regulation. To understand the role of Cdc42 in polarised secretion from cytotoxic T lymphocytes (CTLs) we used CRISPR/Cas9 gene deletion. Although Cdc42-deleted CTLs initially showed reduced cytotoxicity for up to 2 days after CRISPR-mediated deletion, full secretion and cytotoxicity was rapidly restored and even enhanced while CDC42 protein remained absent. In contrast, chemical inhibition of CDC42 using CASIN consistently decreased secretion in wild-type cells, but had no impact on Cdc42-deleted CTLs, confirming the specificity of this inhibitor. Comparative proteomics and transcriptomics of CTLs after Cdc42 deletion revealed transcriptional changes that could support improved T cell function, including compensation via other Rho GTPases. Targeting the promoter region of Cdc42 did not trigger transcriptional adaptation, consistent with a nonsense-mediated decay mechanism of genetic compensation. Our work highlights the importance of taking orthogonal approaches to study protein function and reveals the remarkable robustness of primary T cells to adapt to loss of an essential gene.
Description
Peer reviewed: True
Acknowledgements: We thank Mark Bowen and Matthew Gratian at the CIMR microscopy core facility, and Reiner Schulte and Gabriela Grondys-Kotarba at the CIMR flow cytometry core facility for training, access to equipment, and assistance. We thank Doreen Cantrell, Shalini Pathak, and the FingerPrints Proteomics Facility at University of Dundee for proteomics sample preparation and mass spectrometry. We thank Yukako Asano, Jane Stinchcombe, Martin Limbäck-Stokin, Gurpreet Dhaliwal, Maddie Robertson, and Anna Lippert at CIMR for helpful discussions.
Publication status: Published
Funder: University of Cambridge; doi: http://dx.doi.org/10.13039/501100000735
Journal Title
Conference Name
Journal ISSN
1477-9137
Volume Title
Publisher
Publisher DOI
Rights and licensing
Sponsorship
Wellcome Trust (217100/Z/19/Z)

